1
|
Wise MK, Okuyemi O, Flint M, Biscaye EM, Martins SL, Tessier KM, Traxler SA, Boraas CM. Intrauterine Device Placement Success for Adolescents and Young Adults at Community-Based Reproductive Health Clinics. J Pediatr Adolesc Gynecol 2024; 37:160-164. [PMID: 38072035 PMCID: PMC10994767 DOI: 10.1016/j.jpag.2023.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 11/11/2023] [Accepted: 11/27/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Despite the endorsement of intrauterine device (IUD) use in adolescents and young adults (AYAs) by leading professional organizations and demonstrated acceptance and desirability by AYAs, clinicians may worry about the procedural difficulty of IUD device placement in younger patients. OBJECTIVE The aim of this study was to evaluate the clinical outcomes of first-attempt IUD placement in an AYA population by vaginal delivery (VD) history. STUDY DESIGN We performed a retrospective cohort study of patients under 25 years old at reproductive health clinics with an IUD placement attempt between January 1 and August 31, 2017. We abstracted sociodemographic characteristics, pregnancy history, and procedural characteristics including complications. Bivariate analyses compared successful first-attempt IUD placement by VD history. We also assessed the frequency of secondary clinical outcomes including ancillary measures used, provider type, symptoms reported during the procedure, and complications. RESULTS We included 1325 participants (median age = 21.3 years), including 42 (3.2%) with a previous VD. Nearly all IUD placements were successful on the first attempt (n = 1301, 98.2%) and performed by advanced practice clinicians (n = 1314, 99.2%). First-attempt IUD placement success was similar in those participants with and without VD (P > .999). Ancillary measures other than nonsteroidal anti-inflammatory drugs were used infrequently (n = 16, 3.6%). Among participants with an unsuccessful placement, 66.7% returned, and all had a successful IUD placement on the second attempt. Documented complications within 6 months of placement were rare (n = 29) and mostly comprised expulsions (n = 27, 93.1%). CONCLUSION IUD placement success among AYAs at community-based reproductive health clinics is high and is not associated with a history of VD.
Collapse
Affiliation(s)
- Meredith K Wise
- University of Minnesota Department of Obstetrics, Gynecology and Women's Health, Minneapolis, Minnesota.
| | | | - Maggie Flint
- University of Minnesota Medical School, Minneapolis, Minnesota
| | - Emily M Biscaye
- University of Minnesota Department of Obstetrics, Gynecology and Women's Health, Minneapolis, Minnesota
| | - Summer L Martins
- University of Minnesota Department of Obstetrics, Gynecology and Women's Health, Minneapolis, Minnesota
| | - Katelyn M Tessier
- University of Minnesota Masonic Cancer Center, Biostatistics Core, Minneapolis, Minnesota
| | - Sarah A Traxler
- Planned Parenthood North Central States, St. Paul, Minnesota
| | - Christy M Boraas
- University of Minnesota Department of Obstetrics, Gynecology and Women's Health, Minneapolis, Minnesota
| |
Collapse
|
2
|
Hassan A, Ojanen-Goldsmith A, Hing AK, Mahoney M, Traxler S, Boraas CM. More than tears: associations between exposure to chemical agents used by law enforcement and adverse reproductive health outcomes. Front Epidemiol 2023; 3:1177874. [PMID: 38516336 PMCID: PMC10956352 DOI: 10.3389/fepid.2023.1177874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 07/17/2023] [Indexed: 03/23/2024]
Abstract
Despite routine law enforcement use of chemical agents for crowd control, the reproductive health safety profiles of these products are unknown. Moreover, limited evidence has documented a link between such exposures and adverse reproductive health outcomes including abnormal uterine bleeding and potential pregnancy disruption. This cross-sectional study examined reproductive outcomes in adults with uteri exposed to chemical agents used by law enforcement, more commonly known as "tear gas". Participants were recruited through social media in the wake of police violence protests. Of the 1,276 participants included in analysis, 83% reported experiencing at least one of the outcomes of interest, included uterine cramping (69%), early menstrual bleeding (55%), breast tenderness (30%), and delayed menstrual bleeding (19%). Chemical agent exposure was significantly associated with higher odds of an adverse reproductive health outcome, those with 5 days or more of exposure have 2.6 times the odds (CI: 1.61, 4.22) of adverse outcomes and having a perception that one's menstruation may fluctuate according to psychosocial stressors was associated (OR = 1.94, CI: 1.36, 2.79) with a higher odds of an adverse reproductive health experience. These findings suggest a potential relationship between exposure to chemical agents and adverse reproductive health outcomes. Given the pervasive use of these chemical agents and their potential for reproductive health harm, further investigation into the safety of these products and their impacts on individual and community health is warranted urgently.
Collapse
Affiliation(s)
- Asha Hassan
- Research Division, Planned Parenthood North Central States, Minneapolis, MN, United States
- Center for Antiracism Research for Health Equity, University of Minnesota School of Public Health, Minneapolis, MN, United States
| | | | - Anna K. Hing
- Center for Antiracism Research for Health Equity, University of Minnesota School of Public Health, Minneapolis, MN, United States
| | - Madeline Mahoney
- Research Division, Planned Parenthood North Central States, Minneapolis, MN, United States
| | - Sarah Traxler
- Research Division, Planned Parenthood North Central States, Minneapolis, MN, United States
| | - Christy M. Boraas
- Research Division, Planned Parenthood North Central States, Minneapolis, MN, United States
- Department of Obstetrics, Gynecology, and Women’s Health, University of Minnesota Medical School, Minneapolis, MN, United States
| |
Collapse
|
3
|
Martins SL, Boraas CM. Willingness to use novel reversible methods of male birth control: a community-based survey of cisgender men in the United States. Contracept Reprod Med 2023; 8:41. [PMID: 37563690 PMCID: PMC10413635 DOI: 10.1186/s40834-023-00242-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Accepted: 08/01/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND There is high global demand for new methods of male birth control (MBC). However, contemporary evidence regarding men's method-specific attitudes and their determinants is sparse. METHODS Non-sterilized cisgender men ages 18-45 with recent history of female sex partners were surveyed at a large community event in the Midwestern US. We examined variation in participants' willingness to use MBC by method (gel, pill, injection, implant, and vas occlusion), potential side effects, and potential barriers. We estimated crude and adjusted prevalence ratios (aPRs) for associations between participant characteristics and willingness to use ≥ 1 MBC method. RESULTS Overall, 72% of participants (n = 187; mean age, 29) were very willing to use ≥ 1 MBC method although support for individual methods ranged widely from 62% (pill) to 24% (vas occlusion). In bivariate analysis of sociodemographic and health characteristics, few demonstrated associations with MBC willingness. In a multivariable model, willingness was independently related to age (30-39 vs. 18-29 years old, aPR = 1.24, 95% CI 1.04-1.48) and having ever been tested for HIV (aPR = 1.27, 95% CI 1.07-1.51). Willingness to tolerate side effects was < 10% for most items. The most commonly endorsed barriers to MBC use were high cost (77%) and side effects (66%). CONCLUSIONS Enthusiasm for MBC was high but waned in the context of potential side effects and barriers. Additional research on MBC attitudes in socioeconomically and culturally diverse populations worldwide is sorely needed.
Collapse
Affiliation(s)
- Summer L Martins
- Allina Health, 2925 Chicago Avenue, MS 10105, Minneapolis, MN, 55455, USA
| | - Christy M Boraas
- Department of Obstetrics, Gynecology & Women's Health, University of Minnesota Medical School, Riverside Professional Building, 606 24th Ave. S., Minneapolis, MN, 55454, USA.
| |
Collapse
|
4
|
Koenig LR, Raymond EG, Gold M, Boraas CM, Kaneshiro B, Winikoff B, Coplon L, Upadhyay UD. Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States. Contraception 2023; 121:109962. [PMID: 36736715 PMCID: PMC10759792 DOI: 10.1016/j.contraception.2023.109962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 01/13/2023] [Accepted: 01/20/2023] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Given the substantial barriers to abortion access in the United States, many clinics now mail patients abortion medications. We examined whether dispensing the medications by mail prolonged time to medication use. STUDY DESIGN We analyzed data from no-test medication abortions with medication provided either by mail or in a clinic from 11 United States clinics from February 2020 to January 2021. We examined mean number of days from patients' first contact with the clinic to mifepristone ingestion, its two-component intervals (first contact to medication dispensing and dispensing to mifepristone ingestion), and pregnancy duration at mifepristone ingestion. We used Poisson regression to compare mean outcomes across three dispensing methods: in-person, mailed from the clinic, and mailed from a mail-order pharmacy. RESULTS Among the 2600 records, patients took mifepristone on average at 49 days of gestation (95% CI, 47-51) and 7 days (95% CI, 4-10) after first contact. Mean time from first contact to mifepristone ingestion was 6 days when medications were dispensed in-person and 9 days when mailed (p = 0.38). While time from first contact to dispensing was similar across methods (6 days in-person, 5 days mailed, p = 0.77), more time elapsed from dispensing to mifepristone ingestion when medications were mailed (4 days from clinic, 5 days from mail-order pharmacy) versus dispensed in-person (0.3 days, p < 0.001). Time to mifepristone ingestion was shorter with higher pregnancy duration. Pregnancy duration at ingestion was similar across methods (48 days in-person, 50 days mailed). CONCLUSIONS Mailing medications did not significantly prolong time from patients' first contact with the clinic to mifepristone ingestion or increase pregnancy duration at mifepristone ingestion. IMPLICATIONS Abortion providers should offer a range of medication abortion dispensing options, prioritizing patient preference.
Collapse
Affiliation(s)
- Leah R Koenig
- Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, Oakland, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; Center for Gender and Health Justice, University of California Global Health Institute
| | | | - Marji Gold
- Department of Family and Social Medicine, Montefiore Medical Center, The Bronx, NY, USA
| | | | - Bliss Kaneshiro
- Deparment of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | | | | | - Ushma D Upadhyay
- Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, Oakland, CA, USA; Center for Gender and Health Justice, University of California Global Health Institute.
| |
Collapse
|
5
|
Groene EA, Boraas CM, Smith MK, Lofgren SM, Rothenberger MK, Enns EA. Evaluation of Strategies to Improve Uptake of Expedited Partner Therapy for Chlamydia trachomatis Treatment in Minnesota: A Decision Analytic Model. MDM Policy Pract 2023; 8:23814683221150446. [PMID: 36714792 PMCID: PMC9880578 DOI: 10.1177/23814683221150446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Accepted: 12/18/2022] [Indexed: 01/24/2023] Open
Abstract
Background. Despite the established effectiveness of expedited partner therapy (EPT) in partner treatment of bacterial sexually transmitted infections (STI), the practice is underutilized. Objective. To estimate the relative effectiveness of strategies to increase EPT uptake (numbers of partners treated for chlamydia). Methods. We developed a care cascade model of cumulative probabilities to estimate the number of partners treated under strategies to increase EPT uptake in Minnesota. The care cascade model used data from clinical trials, population-based studies, and Minnesota chlamydia surveillance as well as in-depth interviews of health providers who regularly treat STI patients and a statewide survey of health providers across Minnesota. Results. Several strategies could improve EPT uptake among providers, including facilitating treatment payment (additional 1,932 partners treated) and implementing electronic health record reminders (additional 1,755 partners treated). Addressing concerns about liability would have the greatest effect, resulting in 2,187 additional partners treated. Conclusions. Providers expressed openness to offering EPT under several scenarios, which reflect differences in knowledge about EPT, its legality, and potential risks to patients. While addressing concerns about provider liability would have the greatest effect on number of partners treated, provider education and procedural changes could make a substantial impact. Highlights Addressing provider concerns about expedited partner therapy (EPT) legality and its potential risks would result in the most partners treated for chlamydia.EPT alerts and electronic EPT prescriptions may also streamline partner treatment.Provider education about the legality of EPT and its potential risks and training in counseling patients on EPT could also increase uptake.
Collapse
Affiliation(s)
- Emily A. Groene
- Emily A. Groene, Division of Epidemiology
and Community Health, University of Minnesota School of Public Health, 1300
South 2nd Street, Suite 300, Minneapolis, MN 55454, USA;
()
| | - Christy M. Boraas
- Department of Obstetrics, Gynecology and
Women’s Health, University of Minnesota Medical School, Minneapolis, MN,
USA
| | - M. Kumi Smith
- Division of Epidemiology and Community Health,
University of Minnesota School of Public Health, Minneapolis, MN, USA
| | - Sarah M. Lofgren
- Division of Infectious Diseases and
International Medicine, University of Minnesota Medical School, Minneapolis,
MN, USA
| | - Meghan K. Rothenberger
- Division of Infectious Diseases and
International Medicine, University of Minnesota Medical School, Minneapolis,
MN, USA
| | - Eva A. Enns
- Division of Health Policy and Management,
University of Minnesota School of Public Health, Minneapolis, MN, USA
| |
Collapse
|
6
|
Boraas CM, Carroll A, Hesse SP, Norkett E, Ralph JA. Management of Surgical Abortion Complications. J Gynecol Surg 2022. [DOI: 10.1089/gyn.2022.0065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Christy M. Boraas
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Anna Carroll
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Steven P. Hesse
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Emily Norkett
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Jessika A. Ralph
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| |
Collapse
|
7
|
Groene EA, Boraas CM, Smith MK, Lofgren SM, Rothenberger MK, Enns EA. A Statewide Mixed-Methods Study of Provider Knowledge and Behavior Administering Expedited Partner Therapy for Chlamydia and Gonorrhea. Sex Transm Dis 2022; 49:601-609. [PMID: 35796238 PMCID: PMC9378509 DOI: 10.1097/olq.0000000000001668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Expedited partner therapy (EPT) refers to the practice of having patients diagnosed with chlamydia or gonorrhea deliver medication directly to their partner(s) to treat them presumptively for infection. Although EPT facilitates timely treatment and prevents reinfection, it remains underused. We used findings from key informant interviews to design and implement a statewide survey to estimate knowledge and utilization of EPT and to identify barriers and facilitators to EPT among Minnesota providers. METHODS From November to December 2020, we carried out 15 interviews with health providers who currently provide EPT and coded interviews by recurring themes. We then conducted a statewide online survey on sexually transmitted infection treatment and barriers to EPT, from December 2020 to March 2021. We disseminated the survey to all licensed Minnesota health providers, and those who reported treating bacterial sexually transmitted infections in the past year were included in the study. RESULTS Interview themes included the importance of direct provision of partner medication, administrative/pharmacy barriers to treatment, inclusive EPT eligibility, and patient counseling. Of the 623 health providers who completed the online survey, only 70% thought EPT was legal and only 37% currently offer EPT. Of those who did not provide EPT, 78% said they would under certain circumstances. Barriers included concerns about safety/liability of prescribing without a medical examination, administrative concerns about prescriptions, and patient acceptance. CONCLUSIONS Given that over a quarter of respondents did not know expedited partner therapy (EPT)'s legal status, improving provider education may increase EPT provision. More research is needed on system-level barriers and patient acceptance of solutions identified in this study.
Collapse
Affiliation(s)
- Emily A Groene
- From the Division of Epidemiology and Community Health, University of Minnesota School of Public Health
| | - Christy M Boraas
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School
| | - M Kumi Smith
- From the Division of Epidemiology and Community Health, University of Minnesota School of Public Health
| | - Sarah M Lofgren
- Division of Infectious Disease and International Medicine, University of Minnesota Medical School
| | - Meghan K Rothenberger
- Division of Infectious Disease and International Medicine, University of Minnesota Medical School
| | - Eva A Enns
- School of Public Health, Division of Health Policy and Management, Minneapolis, MN
| |
Collapse
|
8
|
Upadhyay UD, Raymond EG, Koenig LR, Coplon L, Gold M, Kaneshiro B, Boraas CM, Winikoff B. Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study. JAMA Intern Med 2022; 182:482-491. [PMID: 35311911 PMCID: PMC8938895 DOI: 10.1001/jamainternmed.2022.0217] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Screening for medication abortion eligibility typically includes ultrasonography or pelvic examination. To reduce physical contact during the COVID-19 pandemic, many clinicians stopped requiring tests before medication abortion and instead screened patients for pregnancy duration and ectopic pregnancy risk by history alone. However, few US-based studies have been conducted on the outcomes and safety of this novel model of care. OBJECTIVE To evaluate the outcomes and safety of a history-based screening, no-test approach to medication abortion care. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included patients obtaining a medication abortion without preabortion ultrasonography or pelvic examination between February 1, 2020, and January 31, 2021, at 14 independent, Planned Parenthood, academic-affiliated, and online-only clinics throughout the US. EXPOSURES Medications for abortion provided without preabortion ultrasonography or pelvic examination and dispensed to patients in person or by mail. MAIN OUTCOMES AND MEASURES Effectiveness, defined as complete abortion after 200 μg of mifepristone and up to 1600 μg of misoprostol without additional intervention, and major abortion-related adverse events, defined as hospital admission, major surgery, or blood transfusion. RESULTS The study included data on 3779 patients with eligible abortions. The study participants were racially and ethnically diverse and included 870 (23.0%) Black patients, 533 (14.1%) Latinx/Hispanic patients, 1623 (42.9%) White patients, and 327 (8.7%) who identified as multiracial or with other racial or ethnic groups. For most (2626 [69.5%]), it was their first medication abortion. Patients lived in 34 states, and 2785 (73.7%) lived in urban areas. In 2511 (66.4%) abortions, the medications were dispensed in person; in the other 1268 (33.6%), they were mailed to the patient. Follow-up data were obtained for 2825 abortions (74.8%), and multiple imputation was used to account for missing data. Across the sample, 12 abortions (0.54%; 95% CI, 0.18%-0.90%) were followed by major abortion-related adverse events, and 4 patients (0.22%; 95% CI, 0.00%-0.45%) were treated for ectopic pregnancies. Follow-up identified 9 (0.40%; 95% CI, 0.00%-0.84%) patients who had pregnancy durations of greater than 70 days on the date the mifepristone was dispensed that were not identified at screening. The adjusted effectiveness rate was 94.8% (95% CI, 93.6%-95.9%). Effectiveness was similar when medications were dispensed in person (95.4%; 95% CI, 94.1%-96.7%) or mailed (93.3%; 95% CI, 90.7%-95.9%). CONCLUSIONS AND RELEVANCE In this cohort study, screening for medication abortion eligibility by history alone was effective and safe with either in-person dispensing or mailing of medications, resulting in outcomes similar to published rates of models involving ultrasonography or pelvic examination. This approach may facilitate more equitable access to this essential service by increasing the types of clinicians and locations offering abortion care.
Collapse
Affiliation(s)
- Ushma D Upadhyay
- Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
| | | | - Leah R Koenig
- Department of Epidemiology and Biostatistics, University of California, San Francisco
| | | | - Marji Gold
- RHEDI/Montefiore Medical Center, Bronx, New York
| | | | | | | |
Collapse
|
9
|
Chong E, Shochet T, Raymond E, Platais I, Anger HA, Raidoo S, Soon R, Grant MS, Haskell S, Tocce K, Baldwin MK, Boraas CM, Bednarek PH, Banks J, Coplon L, Thompson F, Priegue E, Winikoff B. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic. Contraception 2021; 104:43-48. [PMID: 33781762 PMCID: PMC9748604 DOI: 10.1016/j.contraception.2021.03.019] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 03/10/2021] [Accepted: 03/18/2021] [Indexed: 01/12/2023]
Abstract
OBJECTIVE To present updated evidence on the safety, efficacy and acceptability of a direct-to-patient telemedicine abortion service and describe how the service functioned during the COVID-19 pandemic. STUDY DESIGN We offered the study at 10 sites that provided the service in 13 states and Washington DC. Interested individuals obtained any needed preabortion tests locally and had a videoconference with a study clinician. Sites sent study packages containing mifepristone and misoprostol by mail and had remote follow-up consultations within one month by telephone (or by online survey, if the participant could not be reached) to evaluate abortion completeness. The analysis was descriptive. RESULTS We mailed 1390 packages between May 2016 and September 2020. Of the 83% (1157/1390) of abortions for which we obtained outcome information, 95% (1103/1157) were completed without a procedure. Participants made 70 unplanned visits to emergency rooms or urgent care centers for reasons related to the abortion (6%), and 10 serious adverse events occurred, including 5 transfusions (0.4%). Enrollment increased substantially with the onset of COVID-19. Although a screening ultrasound was required, sites determined in 52% (346/669) of abortions that occurred during COVID that those participants should not get the test to protect their health. Use of urine pregnancy test to confirm abortion completion increased from 67% (144/214) in the 6 months prior to COVID to 90% (602/669) in the 6 months during COVID. Nearly all satisfaction questionnaires (99%, 1013/1022) recorded that participants were satisfied with the service. CONCLUSIONS This direct-to-patient telemedicine service was safe, effective, and acceptable, and supports the claim that there is no medical reason for mifepristone to be dispensed in clinics as required by the Food and Drug Administration. In some cases, participants did not need to visit any facilities to obtain the service, which was critical to protecting patient safety during the COVID-19 pandemic. IMPLICATIONS Medical abortion using telemedicine and mail is effective and can be safely provided without a pretreatment ultrasound. This method of service delivery has the potential to greatly improve access to abortion care in the United States.
Collapse
Affiliation(s)
- Erica Chong
- Gynuity Health Projects, New York, NY, USA,Present address: Reproductive Health Education in Family Medicine, 3544 Jerome Avenue, Bronx, NY 10467.,Corresponding author
| | | | | | | | | | - Shandhini Raidoo
- Department of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA
| | - Reni Soon
- Department of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA
| | | | - Susan Haskell
- carafem, 1001 Connecticut Avenue NW, Washington, DC, USA
| | - Kristina Tocce
- Planned Parenthood of the Rocky Mountains, Denver, CO, USA
| | | | | | | | - Joey Banks
- Planned Parenthood of Montana, Missoula, MT, USA
| | | | | | | | | |
Collapse
|
10
|
Boraas CM, Sanders JN, Schwarz EB, Thompson I, Turok DK. Risk of Pregnancy With Levonorgestrel-Releasing Intrauterine System Placement 6-14 Days After Unprotected Sexual Intercourse. Obstet Gynecol 2021; 137:623-625. [PMID: 33706343 PMCID: PMC7992872 DOI: 10.1097/aog.0000000000004118] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 07/30/2020] [Indexed: 11/26/2022]
Abstract
Pregnancy is unlikely when a levonorgestrel-releasing intrauterine system (52 mg) is placed 6–14 days after unprotected intercourse.
Collapse
Affiliation(s)
- Christy M. Boraas
- University of Minnesota Medical School, 606 24 Avenue South, Minneapolis, MN 55455 USA
| | - Jessica N. Sanders
- University of Utah School of Medicine, 30 N 1900 E, 2B200, Salt Lake City, UT 84132 USA
| | - E. Bimla Schwarz
- University of California Davis School of Medicine, 4860 Y Street, Suites 010 & 0400, Sacramento, CA 95817 USA
| | - Ivana Thompson
- Vanderbilt Health, One Hundred Oaks, 719 Thompson Lane, Suite 27100, Nashville, TN 37204 USA
| | - David K. Turok
- University of Utah School of Medicine, 30 N 1900 E, 2B200, Salt Lake City, UT 84132 USA
| |
Collapse
|
11
|
Shlafer R, Saunders JB, Boraas CM, Kozhimannil KB, Mazumder N, Freese R. Maternal and neonatal outcomes among incarcerated women who gave birth in custody. Birth 2021; 48:122-131. [PMID: 33368480 PMCID: PMC8246999 DOI: 10.1111/birt.12524] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 10/07/2020] [Accepted: 11/22/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND In the United States, the population of incarcerated women has increased by more than 600% since the 1980s. With this rise, correctional facilities have faced new challenges meeting the health care needs of women, especially those who are pregnant. This retrospective cohort study sought to describe five indicators of maternal and neonatal health among women who gave birth in custody, and to compare outcomes among incarcerated women who did and did not receive enhanced pregnancy support. METHODS We used deidentified electronic health records (EHRs) to examine maternal and neonatal birth outcomes (ie, mode of birth, low birthweight, preterm birth, APGAR score, NICU admission) among women who gave birth in custody. Regression models examined differences in outcomes between women who received enhanced pregnancy support-group prenatal education and one-on-one doula visits-and a historical control group of women who received standard prenatal care. RESULTS Adverse maternal and neonatal birth outcomes in this sample were rare. No differences in outcomes were found between incarcerated women who received enhanced pregnancy support and the historical control group. CONCLUSIONS Despite evidence for the benefits of enhanced pregnancy support in the general population, this study did not find differences in outcomes between incarcerated women who did and did not receive support. Integrated data from prison and hospital records are innovative, but effect measurement is limited by sample size. Future research should include primary data collection on maternal, neonatal, and dyadic outcomes longitudinally and across prisons.
Collapse
Affiliation(s)
- Rebecca Shlafer
- Division of General Pediatrics and Adolescent HealthDepartment of PediatricsUniversity of MinnesotaMinneapolisMNUSA
| | - Jennifer B. Saunders
- Division of Health Policy and ManagementSchool of Public HealthUniversity of MinnesotaMinneapolisMNUSA
| | - Christy M. Boraas
- Department of Obstetrics, Gynecology and Women’s HealthMedical SchoolUniversity of MinnesotaMinneapolisMNUSA
| | - Katy B. Kozhimannil
- Division of Health Policy and ManagementSchool of Public HealthUniversity of MinnesotaMinneapolisMNUSA
| | | | - Rebecca Freese
- Biostatistical Design and Analysis CenterClinical and Translational Science InstituteUniversity of MinnesotaMinneapolisMNUSA
| |
Collapse
|
12
|
Martins SL, Boraas CM. Contraceptive counselling: an essential travel medicine service. J Travel Med 2020; 27:5762312. [PMID: 32104880 DOI: 10.1093/jtm/taaa023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 02/19/2020] [Accepted: 02/24/2020] [Indexed: 11/12/2022]
Abstract
Non-physician healthcare practitioners are increasingly providing pre-travel care, including completing risk assessments and prescribing medications and vaccines. While this increases pre-travel care access, the quality of this care must be ensured. Doing so requires translation of existing prescribing competencies and best practices in competence development into policies regulating pre-travel care.
Collapse
Affiliation(s)
- Summer L Martins
- Department of Obstetrics, Gynecology & Women's Health, University of Minnesota Medical School, Riverside Professional Building 606 24th Avenue South, Minneapolis, Minnesota 55454, USA
| | - Christy M Boraas
- Department of Obstetrics, Gynecology & Women's Health, University of Minnesota Medical School, Riverside Professional Building 606 24th Avenue South, Minneapolis, Minnesota 55454, USA
| |
Collapse
|
13
|
Boraas CM, Chappell CA, Krajewski CM. Use of an endotracheal tube for surgical abortion complicated by a leiomyomatous uterus: a case report. J Med Case Rep 2017; 11:236. [PMID: 28838323 PMCID: PMC5571575 DOI: 10.1186/s13256-017-1408-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Accepted: 07/27/2017] [Indexed: 11/10/2022] Open
Abstract
Background Abnormal uterine anatomy, especially leiomyomas, can significantly impact the difficulty and potential morbidity of surgical uterine evacuation. To avoid hysterotomy and/or hysterectomy, limited evidence exists to guide surgical uterine evacuation when pregnancy tissue is inaccessible with routine instruments. Case presentation A 41-year-old G4P1021 African American woman at 14 4/7 weeks’ gestation was referred for surgical-induced abortion in the setting of an enlarged leiomyomatous uterus. Two large opposing leiomyomas at the internal cervical os rendered pregnancy tissue inaccessible with routine gynecologic surgical instruments. With ultrasound guidance, an endotracheal tube was connected to routine electric suction and utilized to complete uterine evacuation. Conclusions With distorted or markedly enlarged uterine anatomy rendering pregnancy tissue inaccessible with routine surgical instruments, the minimally invasive use of an endotracheal tube may aid completion of uterine evacuation for surgical uterine evacuation.
Collapse
Affiliation(s)
- Christy M Boraas
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, 606 24th Avenue S, Minneapolis, MN, 55454, USA.
| | - Catherine A Chappell
- Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA, 15213, USA
| | - Colleen M Krajewski
- Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA, 15213, USA
| |
Collapse
|
14
|
Paul J, Boraas CM, Duvet M, Chang JC. YouTube and the single-rod contraceptive implant: a content analysis. ACTA ACUST UNITED AC 2017; 43:195-200. [PMID: 28108504 DOI: 10.1136/jfprhc-2016-101593] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 11/18/2016] [Accepted: 12/21/2016] [Indexed: 11/03/2022]
Abstract
BACKGROUND Since the internet has become an important source of contraceptive information with YouTube.com as the second most visited site, we analysed contraceptive implant YouTube videos for content and clinical accuracy. METHODS Using the terms 'contraceptive implant', 'Nexplanon' and 'Implanon', the top 20 results on YouTube by relevance and view count were identified. After excluding duplicates, single-rod implant videos in English were included. Videos were classified as providing a professional or patient perspective. Views, duration and comments were noted. Videos were rated for reliability, global quality scale and whether they were positive or negative about the implant. Inter-rater agreement was measured. RESULTS A total of 120 videos were retrieved; 52 were eligible for review. Less than 23% were professional videos; the majority reported patient experience (46% testimonials, 27% real-time procedure videos, 4% other). Patient videos had been posted a significantly longer duration of time than professional videos (364 vs 188 days, p=0.02), were less reliable (p≤0.0001) and were of lower global quality (p<0.0001). Some 61% of implant testimonial videos were rated as 'positive experiences' and inter-rater agreement was very good (κ=0.81). All testimonials mentioned side effects, commonly irregular bleeding and discomfort with insertion. A minority (26%) reported misinformation. CONCLUSIONS This study found that most of the information on YouTube pertaining to contraceptive implants is accurate, is presented from the patient's perspective, and promotes the method's use.
Collapse
Affiliation(s)
- Jennifer Paul
- Kaiser Permanente, Greater Baltimore Medical Center, 7141 Security Boulevard, Baltimore, MD, USA.,Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Christy M Boraas
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.,Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, Minneapolis, MN, USA
| | - Mildred Duvet
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.,Department of Obstetrics and Gynecology, Leigh Valley Health Network, Allentown, PA, USA
| | - Judy C Chang
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.,Magee-Womens Research Institute, Pittsburgh, PA, USA.,Center for Research in Health Care/Center for Women's Health Research and Innovation, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| |
Collapse
|